179 unknown, 175 completed, 87 recruiting, 78 terminated. 620 Phase 2, 128 Phase 1, 47 Phase 3.
Follow Hepatocellular Carcinoma: new trials by email Literature Review of Hepatocellular Carcinoma trials Research Report on Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC Lenvatinib, Partial transarterial chemoembolization (TACE) - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 40 | 2026-11-30 | 2026-11-03 |
| Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma BGB-B2033 - Hepatocellular Cancer, Liver Cancer | Phase 2 | Not yet recruiting | BeOne Medicines | 100 | 2026-11-30 | 2026-11-03 |
| Chemotherapy-Minimized Blank Microsphere Transarterial Embolization (BMS-TACE) in Hepatocellular Carcinoma Resistant to FOLFOX-Based Hepatic Arterial Infusion Chemotherapy BMS-TACE, Pirarubicin, Blank microspheres - Hepatocellular Carcinoma, Liver Neoplasms | Phase 2 | Recruiting | Sun Yat-sen University | 43 | 2026-10-20 | 2026-11-19 |
| Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy - Hepatocellular Carcinoma | Phase 2 | Recruiting | Anhui Provincial Hospital | 60 | 2026-09-16 | 2026-09-21 |
| Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma Regorafenib, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization - Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 2 | Withdrawn | University of Miami | 2026-08-01 | 2026-06-15 | |
| Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma NRT6003 Injection - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Second Affiliated Hospital of Guangzhou Medical University | 20 | 2026-06-22 | 2026-06-18 |
| 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) Lu-PSMA-617 - Liver Cancer, Hepatocellular Carcinoma | Phase 2 | Recruiting | Melissa Lumish | 10 | 2026-06-01 | 2026-05-08 |
| Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer Durvalumab, Zanzalintinib - Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Not yet recruiting | Amit Mahipal | 16 | 2026-05-01 | 2026-05-05 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) MRG006A, Pucotenlimab, Bevacizumab - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Lepu Biopharma Co., Ltd. | 160 | 2026-04-08 | 2026-07-28 |
| Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Hydroxychloroquine, Lipiodol, Placebo - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 93 | 2026-04-01 | 2026-11-17 |
| Clinical Trial of TB511 in Advanced Solid Tumors TB511, Keytruda - NSCLC, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Twinpig Biolab, Inc. | 12 | 2026-03-01 | 2025-11-25 |
| Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma sintilimab combined with bevacizumab biosimilar - Hepatocellular Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Sun Yat-sen University | 37 | 2026-01-14 | 2026-01-16 |
| β-alanine in the Treatment of Advanced Hepatocellular Carcinoma Atezolizumab combined with bevacizumab combined with β- alanine, Atezolizumab combined with bevacizumab - Hepatocellular Carcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 158 | 2025-12-24 | 2026-01-05 |
| A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Zhongshan Hospital | 222 | 2025-12-22 | 2025-12-30 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. PF-08634404, Ipilimumab - Carcinoma, Hepatocellular, Hepatocellular Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 138 | 2025-12-01 | 2026-10-08 |
| SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma Systemic therapy, Radiotherapy - Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Shandong Cancer Hospital and Institute | 2 | 2025-11-30 | 2026-11-18 |
| Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma Durvalumab Plus Tremelimumab, HAIC (GEMOX) - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Recruiting | UNICANCER | 196 | 2025-11-14 | 2026-02-03 |
| Patient Preference for Subcutaneous vs. Intravenous Immune Therapy nivolumab, pembrolizumab - Renal Cell Carcinoma, Non Small Cell Lung Cancer | Phase 2 | Recruiting | Diwakar Davar | 880 | 2025-11-04 | 2026-04-16 |
Showing 20 of 620. Sign in to see all of them.
Carcinoma, Hepatocellular (620) · Liver Neoplasms (82) · Carcinoma, Non-Small-Cell Lung (26) · Colorectal Neoplasms (24) · Neoplasms (24) · Stomach Neoplasms (21) · Carcinoma, Renal Cell (20) · Cholangiocarcinoma (18) · Melanoma (14) · Neoplasm Metastasis (12) · Pancreatic Neoplasms (11) · Squamous Cell Carcinoma of Head and Neck (10) · Carcinoma (9) · Fibrosis (9) · Urinary Bladder Neoplasms (9)
Digestive System Diseases (618) · Neoplasms by Histologic Type (618) · Neoplasms by Site (618) · Neoplasms, Glandular and Epithelial (618) · Adenocarcinoma (617) · Digestive System Neoplasms (614) · Liver Diseases (612) · Carcinoma (611) · Neoplasms (596) · Liver Neoplasms (538) · Gastrointestinal Diseases (43) · Pathological Conditions, Signs and Symptoms (39) · Gastrointestinal Neoplasms (38) · Pathologic Processes (37) · Lung Diseases (31)
Sorafenib (63) · Bevacizumab (53) · lenvatinib (52) · Nivolumab (35) · sintilimab (30) · durvalumab (29) · atezolizumab (26) · pembrolizumab (26) · apatinib (23) · Fluorouracil (19) · Oxaliplatin (19) · camrelizumab (18) · tremelimumab (17) · Folfox protocol (16) · Radiosurgery (16)
Sun Yat-sen University (43) · Fudan University (13) · National Cancer Institute (NCI) (11) · Shanghai Zhongshan Hospital (11) · Tianjin Medical University Cancer Institute and Hospital (11) · Guangxi Medical University (10) · Seoul National University Hospital (9) · Zhejiang University (9) · Eastern Hepatobiliary Surgery Hospital (8) · Asan Medical Center (7) · National Taiwan University Hospital (7) · University Health Network, Toronto (7) · Akeso (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Peking Union Medical College Hospital (6)
China (236) · United States (165) · South Korea (62) · Taiwan (56) · France (36) · Spain (30) · Germany (26) · Hong Kong (26) · Italy (24) · Canada (21) · Japan (21) · Singapore (19) · United Kingdom (16) · Belgium (13) · Israel (7)
Ming Shi, MD (8) · Tim F Greten, M.D. (6) · David Hsieh, MD (4) · Feng Shen, M.D. (3) · Gao-Jun Teng, MD (3) · Jin Woo Choi, MD, PhD (3) · Lequn Li, PhD (3) · Mi-Sook Kim, MD, PhD (3) · Mian Xi, MD (3) · Peng Wang, MD (3) · Xiaodong Wang, MD (3)
PMID 36852452, PMID 12049862, PMID 19192962, PMID 12540794, PMID 28434648, PMID 29366520, PMID 29543938, PMID 29875066, PMID 31401903, PMID 33856599, PMID 34143971, PMID 36529152, PMID 37981041, PMID 39437804, PMID 11419162, PMID 11668491, PMID 11981766, PMID 12091661, PMID 14667750, PMID 15508079, PMID 15508084, PMID 15623621, PMID 15831268, PMID 15868910, PMID 16495695, PMID 16527888, PMID 16951235, PMID 17543307, PMID 18565579, PMID 18834631, PMID 18981929, PMID 19097774, PMID 20149262, PMID 20332205, PMID 20390419, PMID 20516446, PMID 20717115, PMID 20724077, PMID 20839057, PMID 21058409, PMID 21123824, PMID 21264826, PMID 21277098, PMID 21321535, PMID 21338641, PMID 21487286, PMID 21935635, PMID 22033636, PMID 22075702, PMID 22210086
2018 (3), 2019 (3), P30CA060553 (3), 2015 (2), 2017 (2), 2023 (2), P30CA012197 (2), 2005 (1), 2008 (1), 2014 (1), 2016 (1), 2025 (1), I01CX002542 (1), N01CN00035 (1), N01CN00042 (1)